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Despite improvements in technique and experi-
ence gained in clinical microvascular surgery, small
vessel thrombosis after operative procedures remains
a considerable uncertainty in vascular and recon-
structive surgery, even in the hands of the most tech-
nically experienced physicians.1-4 To prevent the
manifestation of thrombosis, a variety of anticoagu-
lation and antiplatelet aggregation agents have been
introduced into clinical practice,5-7 but a definitive
choice for the most effective prophylaxis has not yet
been determined.
Hirudins, which are potent thrombin inhibitors,
are a group of highly homologous polypeptides
derived from the medicinal leech, which have been
known since ancient times to prevent blood from
clotting. Recombinant hirudins (r-hirudins) have
been produced and suggested for use in antithrom-
botic and fibrinolytic therapy.8,9 They have an
extremely high and specific affinity for thrombin10
and thus inhibit thrombin-induced platelet aggrega-
tion11 and accretion of thrombin into blood cell
clots.12 Therefore, r-hirudin may be a particular can-
didate to prevent thrombosis of microvessels during
vascular and reconstructive surgery. To prove this
hypothesis, we used a novel in vivo microcirculation
model for light/dye-induced thrombosis13 to study
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bus formation but also promotes vessel recanalization, thus supporting its use in clini-
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the effect of r-hirudin on microvascular clot forma-
tion and microvessel recanalization. 
MATERIALS AND METHODS
Animals. Sixteen female homozygous (hr/hr)
hairless mice (8 to 10 weeks old, 22 to 26 g of body
weight)14 were used in the study. The animals were
housed one per cage and had access to standard labora-
tory food and water ad libitum. The experimental pro-
tocol was approved by the local animal care committee.
Microcirculatory model. We used the ear of the
hr/hr hairless mouse, which was first introduced as a
sophisticated model for the study of skin microcircu-
lation in 1980 by Eriksson et al.15 Based on this
report, the hairless mouse ear was further used by
others to investigate the microvascular response to a
variety of different pathologic conditions, including
thermal injury,16 flap failure,17 and wound healing.18
Because the hairless mouse ear allows excellent visu-
alization of the cutaneous microvessels without the
need for operative preparation procedures, we adopt-
ed this tool in a previous study to establish a model
for quantitative in vivo microscopic analysis of
thrombus formation and vessel recanalization of both
arterioles and venules.13 The model permits repeated
analysis of the process of clot formation, vascular
occlusion, and recanalization, as well as the determi-
nation of the alteration of individual microcirculato-
ry parameters, such as vessel diameter, red blood cell
velocity, endothelial permeability, vasomotion, and
leukocyte-endothelial cell interaction. Analysis of the
antithrombotic activity of heparin revealed a signifi-
cant delay in thrombus formation, similar to that
reported by the use of other models, such as electri-
cal stimulation-induced occlusive thrombosis in the
rabbit and stasis-induced thrombosis in mice,19,20
indicating the validity of the model for the study of
antithrombotic and thrombolytic therapy.
Thrombus induction. For the induction of
thrombosis, the ears of the anesthetized mice (90
mg/kg ketamine/25 mg/kg xylazine intraperitoneal)
were placed under a Leitz Orthoplan microscope.
Thrombus formation was induced photochemically
after the intravenous injection of 0.15 ml of 5% fluo-
rescein isothiocyanate (FITC)-labeled dextran (molec-
ular weight, 150,000; Sigma Chemical, St. Louis,
Mo.) by continuous local light exposure (wavelength,
450 to 490 nm) to the individual microvessels under
investigation using a · 63 water-immersion objective.
Light exposure (field, 150 m m in diameter), which
could be directed selectively to the vessel under inves-
tigation without alteration of distant tissue areas, was
terminated 10 seconds after complete vessel occlusion.
Intravital fluorescence microscopy. Micro-
circulatory parameters were analyzed in identical
microvessels (one or two arterioles and one to three
venules per ear) before thrombus induction (base-
line); during the process of thrombus formation;
and at 5 minutes, 30 minutes, and 24 hours after
vessel occlusion by means of intravital fluorescence
microscopy using a · 25 water-immersion objective.
Animals received r-hirudin (HBW 023; recombi-
nant [Leu0,Thr1] desulfatohirudin, 1 mg/kg of
body weight intravenous; Hoechst Marion Roussel,
Frankfurt, Germany) directly before the light/dye
exposure (n = 8). Animals that received equivalent
volumes of saline served as controls (n = 8).
Contrast enhancement for visualization of the
microcirculation was provided by FITC-labeled dex-
tran, whereas leukocyte flow dynamics and leuko-
cyte-endothelial cell interactions were studied after
in vivo nuclear staining with rhodamine 6G (molec-
ular weight, 476; Sigma Chemical). The fluorescent
tracers were injected intravenously 5 minutes before
the start of the experiment and before the repeated
analysis at 24 hours.
The epi-illumination setup consisted of a 100 W
mercury lamp and a Ploemo-Pak illuminator equipped
with an I2 blue filter (excitation wavelength, 450 to 490
nm; emission wavelength, greater than 515 nm) and an
N2 green filter (excitation wavelength, 530 to 560 nm;
emission wavelength, greater than 580 nm). The move-
ment of the microscope platform in x/y directions was
achieved with the use of two computer-controlled step-
ping motors, which allowed repeated measurements in
identical microvessels throughout the experiment.
Microscopic images were recorded with a charge-cou-
pled device video camera (CF 8/1 FMC; Kappa,
Gleichen, Germany) and stored on videotape for off-
line evaluation using computer-assisted image analysis
systems (CapImage; Zeintl Software, Heidelberg,
Germany21; Capiflow; Capiflow AB, Kista, Sweden22).
Parameters. The analysis of the kinetics of
thrombus formation included the determination of
the time periods until (1) platelet deposition was
first observed at the endothelial lining (platelet-
endothelial cell interaction), (2) the inner luminal
diameter of the microvessels was reduced to 50% by
the growing thrombus, and (3) blood flow ceased
due to complete vessel occlusion. The incidence of
microvascular recanalization was analyzed at 5 min-
utes, 30 minutes, and 24 hours after thrombus for-
mation. Measurements of microcirculatory parame-
ters included the evaluation of (1) microvascular wall
shear rate, based on the Newtonian definition (8 ·
V/D, where V is the red blood cell centerline veloc-
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ity divided by 1.6 according to the Baker-Wayland
factor,23 and D is the individual inner vessel diame-
ter); (2) endothelial integrity disruption (i.e.,
extravasation of macromolecular FITC-dextran
[assessed by the ratio of extravascular and intravas-
cular fluorescence intensities]); (3) incidence of
vasomotion (defined as rhythmic changes in the
diameter of the vessel segment under investigation
with frequencies in a range of ~2 to ~30 cycles per
minute); (4) venular leukocyte flux (defined as all
leukocytes passing an imaginary gate during the
observation period of 30 seconds); and (5) leuko-
cyte adherence (defined as cells that did not move or
detach during the observation period of 30 seconds
within a 100 m m segment of the blood vessel).
Statistics. Data are presented as mean ± SEM.
After testing for normal distribution, analysis of vari-
ance was followed by appropriate comparison
(Student’s t test) including Student-Newman-Keuls
test. Fisher’s exact test was used for statistical analy-
sis of the incidence of vasomotion and recanaliza-
tion. Values of P < 0.05 were taken to indicate sta-
tistical significance. Statistical analyses were per-
formed using the software package SigmaStat
Version 1.0 (Jandel, San Rafael, Calif.).
RESULTS
Thrombus formation and vascular recanaliza-
tion. In venules, pretreatment with r-hirudin
resulted in delayed first platelet deposition at the
Fig. 1. Kinetics of thrombus formation in acute
light/dye-induced thrombosis, including time points of
first platelet deposition at the endothelial lining (A),
reduction in inner luminal diameter to 50% (B), and com-
plete vessel occlusion (C) in nontreated controls and r-
hirudin-treated animals (1 mg/kg of body weight intra-
venous). Values are given as mean ± SEM. *P < 0.05 vs
control, #P < 0.05 vs venules.
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endothelial lining (173 ± 11 seconds) compared
with controls (59 ± 4 seconds, P < 0.05) (Fig. 1, A).
Vessel lumen was found to be reduced to 50% by
thrombus deposits after 342 ± 54 seconds in the r-
hirudin group but after 228 ± 27 seconds in controls
(P < 0.05) (Fig. 1, B). Finally, complete venular
occlusion in r-hirudin-treated animals was observed
after 541 ± 85 seconds, whereas in nontreated con-
trols, venules were found to be completely obstruct-
ed by the thrombus after 344 ± 43 seconds (P <
0.05) (Fig. 1, C).
In arterioles, first platelet deposition also was sig-
nificantly (P < 0.05) delayed after r-hirudin pretreat-
ment (381 ± 80 seconds) compared with nontreated
controls (137 ± 25 seconds) (Fig. 1, A). However,
the time until the arteriolar lumen was reduced to
50% was only slightly increased in r-hirudin-treated
animals (627 ± 49 vs 501 ± 71 seconds) (Fig. 1, B).
The time until arterioles were found to be com-
pletely occluded did not differ between the two
groups (925 ± 78 vs 854 ± 60 seconds) (Fig. 1, C).
In both groups, vascular recanalization was
found in neither venules nor arterioles after 5 and 30
minutes of complete vessel occlusion. After 24
hours, however, both arterioles and venules of r-
hirudin-treated animals showed a distinct rate of
recanalization, which compared with nontreated
animals was significantly higher in arterioles (P <
0.05) but only slightly (P > 0.05) higher in venules
(Fig. 2, A). The inner luminal diameter of recanal-
ized venules was found to be larger after hirudin
treatment (79% ± 7.7% of baseline vs 49% ± 5.3% in
controls; P < 0.05), whereas possible differences in
the inner luminal diameter of arterioles could not be
determined due to the lack of recanalized arterioles
in the control group (Fig. 2, B).
Microcirculatory alterations. Arterioles and
venules did not show significant differences in wall
shear rates between the groups at baseline and at 1
minute before vessel occlusion. However, a distinct
reduction in wall shear rates was found in both groups
at 1 minute before vessel occlusion (Table I). In addi-
tion, after 24 hours, wall shear rates of recanalized
venules in hirudin-treated animals (55 ± 11.7 sec–1)
differed significantly (P < 0.05) from baseline values
(121 ± 23.7 sec–1) and from the values of recanalized
venules in nontreated controls after 24 hours (117 ±
24.8 sec–1).
Table I. Wall shear rates at baseline and 1 minute before complete vessel occlusion in arterioles and
venules of the ear of the hairless mouse
Arterioles Venules
r-Hirudin Controls r-Hirudin Controls
Baseline (sec–1) 378 ± 73.3 272 ± 43.2 121 ± 23.7 127 ± 24.9
1 min before vessel occlusion (sec–1) 99 ± 21.6* 71 ± 12.9* 29 ± 4.1* 49 ± 11.3*
Controls, nontreated animals; r-hirudin, r-hirudin-treated animals (1 mg/kg of body weight intravenous).
Data are presented as mean ± SEM.
*p < 0.05 vs baseline.
Table II. Endothelial integrity disruption as analyzed by the extravasation of FITC-dextran 150,000 in
microvessels of hirudin-treated and nontreated animals
Arterioles Venules
r-Hirudin Controls r-Hirudin Controls
Baseline 0.50 ± 0.03 0.52 ± 0.09 0.53 ± 0.05 0.49 ± 0.11
–1 min 0.52 ± 0.12 0.43 ± 0.05 0.56 ± 0.14 0.39 ± 0.07
Occlusion 0.49 ± 0.06 0.34 ± 0.11 0.55 ± 0.10 0.44 ± 0.12
5 min 0.91 ± 0.03* 0.96 ± 0.17* 0.89 ± 0.11* 0.91 ± 0.09*
30 min 1.02 ± 0.05* 0.97 ± 0.06* 1.02 ± 0.08* 0.94 ± 0.04*
24 hr 0.73 ± 0.06* 0.86 ± 0.08* 0.66 ± 0.11 0.64 ± 0.10
Controls, nontreated animals; r-hirudin, r-hirudin-treated animals (1 mg/kg of body weight intravenous).
Time points are baseline, 1 minute before complete vessel occlusion (–1 min), vessel occlusion, and 5 min, 30 min, and 24 hr after
thrombus formation.
Data are mean ± SEM.
*p < 0.05 vs baseline; comparison between the groups showed no significant differences.
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Endothelial integrity disruption in arterioles and
venules increased significantly (P < 0.05) during the
early phase (5 and 30 minutes) after vessel occlusion
in both groups and did not recover to baseline val-
ues after the 24-hour observation period. There was
no difference between the two groups studied
(Table II).
Under baseline conditions, a comparable inci-
dence of arteriolar vasomotion was found in both
groups (r-hirudin, 31% [4 of 13]; controls, 25% [3
of 12]). In contrast, distinct differences (P < 0.05)
were found at 1 minute before complete vessel
occlusion, with a marked increase in the incidence of
arteriolar vasomotion in nontreated controls (83%
[10 of 12]) compared with r-hirudin-treated animals
(15% [2 of 13]). Venular vasomotion was not
observed in animals that received r-hirudin or in
nontreated controls.
Inflammatory response. An evaluation of
leukocyte flux in venules revealed no significant dif-
ference between the groups at all time points stud-
ied. In addition, leukocyte flux at baseline did not
differ between vessels that were found to be recanal-
ized after the 24-hour observation period and those
that remained occluded (Table III). Furthermore, a
comparison of leukocyte flux in recanalized vessels
with that at baseline showed no significant differ-
ences (Table III). 
In contrast, in recanalized venules, leukocyte
adhesion was found to be significantly (P < 0.05)
increased in both treated (4.2 ± 1.0 per 100 m m)
and nontreated (2.5 ± 0.3 per 100 m m) animals
compared with baseline values (1.0 ± 0.7 and 0.33 ±
0.2 per 100 m m). Analysis between the groups
showed no statistically significant differences. An
analysis of leukocyte adhesion in arterioles also
showed adherent cells 24 hours after thrombus
induction in recanalized vessels (only r-hirudin-
treated mice) in a similar range (4.0 ± 0.5 per 100
m m) as measured in venules, whereas no arteriolar
leukocyte adherence was found in either of the
groups under baseline conditions.
DISCUSSION
Until the discovery of heparin in 1916 by
McLean, hirudins, which are extracted from the heads
of medicinal leeches, were the only means of prevent-
ing blood from clotting. Since the late 1980s, when
genetically engineered hirudins became available,
intensive experimental and clinical research has been
initiated to evaluate their properties in different clini-
cal settings. In a variety of trials, hirudins have shown
Fig. 2. Incidence of vessel recanalization (A) and inner luminal diameter of recanalized ves-
sels (B) in nontreated controls and r-hirudin-treated animals (1 mg/kg of body weight intra-
venous) at 24 hours after thrombus formation. Values are given as mean ± SEM. *p < 0.05 vs
control, #p < 0.05 vs venules.
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an extremely high and specific affinity for thrombin.
When bound to thrombin in a 1:1 complex, hirudin
forms a cap over the active site, thus preventing access
of substrates and presumably inhibiting the enzyme.10
Even when thrombin is already bound to a thrombus,
hirudin is able to block the enzyme and therefore pre-
vent the growth of a preexistent thrombus.24 More-
over, it reduces the accretion of thrombin into blood
clots.12 In addition to its ability to limit thrombin-
induced platelet aggregation, hirudin has been found
to be effective in the reduction in platelet aggregates
on the endothelial wall of deeply damaged blood ves-
sels24 and in the inhibition of the vasoconstrictive
action of thrombin in deendothelialized vessels.25
Furthermore, hirudin inhibits the activation of certain
cofactors (V, VIII, and Xa)26,27 and blocks the release
of thromboxane A2, platelet factor 4, and plasmino-
gen activator inhibitor-1 by platelets, as well as the
expression of procoagulant phospholipids on the sur-
face of platelets,28 which is of particular importance in
the role of platelets in thrombus formation. Sur-
prisingly, most of the inhibitory mechanisms remain
beyond the time at which hirudin is removed from
the circulation through excretion.29 This effect might
be explained by the tight binding of recombinant
hirudin to thrombus-bound thrombin; it was con-
cluded that the biologic efficacy of hirudin is longer
than that predicted on the basis of its plasma levels.30
Apart from its anticoagulant effects, the hirudins
are pharmacodynamically inert and well tolerated in
vivo.31,32 Hirudins are fairly short-acting agents
with an overall half-life of 40 to 120 minutes.33
They are excreted unchanged in urine as their major
route of elimination.33
To determine the potential use of hirudins in the
prevention of thrombosis after microsurgical inter-
vention, we investigated the effect of r-hirudin
(HBW 023) on thrombus formation and recanaliza-
tion in a recently established microvascular throm-
bosis model.13 Pretreatment with r-hirudin (1
mg/kg intravenous) before photochemical induc-
tion of thrombus formation led to a significant delay
of first cell deposition at the endothelial lining in
both arterioles and venules, a result similar to the
data obtained by Just et al.34 in mesenteric vessels in
a laser-induced thrombosis model. Our study
extends this knowledge by demonstrating that r-
hirudin in vivo effectively delays the entire process of
thrombus formation in venules but only slightly in
arterioles. This different effect can be due to the fact
that venules may be more sensitive to light injury as
a result to their thinner walls. However, it may also
be due to the different reactions of arterioles and
venules to light/dye exposure, as indicated by Sato
and Ohshima,35 or to different antiaggregatory or
proaggregatory substances released by venular as
opposed to arteriolar endothelium.36
In addition, hirudin significantly increased the rate
of vessel recanalization. These data confirm the effec-
tiveness of r-hirudin in vivo as hypothesized in previ-
ously published reports, which have described a
potentiation of fibrinolysis by hirudin in vitro.7,34,37
From these results, it was speculated that clots that
form in the presence of partially inhibited thrombin
are different from those that form when the thrombin
is fully active. Our current in vivo study demonstrates
that r-hirudin indeed effectively increases the rate of
recanalization of thrombosed microvessels.
The application of r-hirudin did not affect the
wall shear rates during thrombus formation.
However, markedly decreased values were measured
in the recanalized venules of treated animals com-
pared with controls. The explanation for this finding
might be the larger inner luminal diameter of the
recanalized venules in the hirudin-treated animals,
which leads to decreased red blood cell velocities
and, consequently, based on the Newtonian defini-
tion, reduced wall shear rates in these vessels.
Whether this effect of r-hirudin influences the rate of
rethrombosis was not investigated in this study, but
it must be taken into consideration as an additional
hirudin-induced mechanism of protection, at least
Table III. Leukocyte flux at baseline and 24 hours after thrombus formation in both venules that either
were recanalized or remained occluded within the 24-hour observation period
Occluded Recanalized
r-Hirudin Controls r-Hirudin Controls
Baseline (cells/30 sec) 9.3 ± 2.2 14.4 ± 6.8 11.1 ± 2.4 15.7 ± 5.6
24 hr after vessel thrombosis (cells/30 sec) ____ ____ 8.2 ± 1.7 12.2 ± 2.4
Controls, nontreated animals; r-hirudin, hirudin-treated animals (1 mg/kg of body weight intravenous).
Data are presented as mean ± SEM.
for venules, for which it is known that lower shear
rates reduce the risk of thrombus formation.35
The extent of endothelial integrity disruption did
not differ between the two groups. This can be con-
sidered an indicator of similar endothelial cell dam-
age in both groups induced by light/dye exposure
and thus underlines the results that r-hirudin does
not prevent light/dye-induced endothelial injury as
the cause of thrombosis but instead delays the
process of thrombus formation.
According to our previous results,13 a markedly
increased incidence of vasomotion in arterioles of
the nontreated animals was observed before com-
plete thrombotic vessel occlusion. Considering that
endothelial cell damage induces a complex response
with a variety of protective mechanisms to prevent
thrombosis, it was speculated that vasomotion might
be one of these endogenic mechanisms, acting pref-
erentially in arterioles.13 Strikingly, arteriolar vaso-
motion could not be induced during thrombus for-
mation in arterioles of r-hirudin-treated animals.
This is probably due to the inhibitory action of r-
hirudin on smooth muscle cell retraction.38 In fact,
the inhibition of vasomotion by r-hirudin may
explain its reduced effectiveness in preventing arteri-
olar compared with venular thrombosis in our
model.
The application of r-hirudin did not significantly
affect leukocyte flux and adhesion in arterioles and
venules at any of the investigated time points.
However, in both groups, distinct leukocyte adhe-
sion was found in recanalized microvessels. The
increased leukocyte adhesion may be interpreted as a
response to injury of the vessel wall (i.e., endothelial
cell damage) or may be due to changes in local flow
conditions (i.e., wall shear rate). The former expla-
nation is supported by intravital microscopic studies,
demonstrating leukocyte adhesion in arterioles after
laser-induced cell damage.39 The latter explanation
is supported by studies demonstrating that reduc-
tion in shear stress indeed also induces leukocyte
adhesion in arterioles.40 The fact that leukocytes
adhere to arteriolar endothelium may be surprising,
however, given that light/dye-induced thrombosis is
mediated by oxygen radicals; this is in accordance
with experiments by others demonstrating oxygen
radical-induced arteriolar leukocyte adhesion in
ischemia/reperfusion-challenged kidneys.37
In summary, the results of our study indicate that
pretreatment with r-hirudin delays the process of
thrombus formation and improves recanalization
rate of microvessels occluded by thrombi. Our find-
ings, together with those of others,41-43 support a
potentially beneficial use of r-hirudin not only in
clinical microvascular surgery but also for prophy-
laxis and treatment of postoperative venous throm-
bosis/diffuse microthrombosis, prevention of arte-
rial thrombosis in large vessel surgery, and enhance-
ment of fibrinolytic therapy and/or angioplasty to
prevent reocclusion.
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